ZFN CFTR-transduced autologous induced pluripotent stem cell therapy (Sangamo)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameZFN CFTR-transduced autologous induced pluripotent stem cell therapy (Sangamo)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A